<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="has been marked as a highly pathogenic coronavirus of COVID-19" exact="disease" post="into the human population, causing over 5.5 million confirmed"/>
 <result pre="discussions of the status of COVID-19. Graphical abstract The possible" exact="viral" post="entry and replication mechanism of SARS-CoV-2 and crucial targets"/>
 <result pre="In December 2019, a new coronavirus (CoV) correlated with human" exact="respiratory" post="disease was firstly reported causing pneumonia and death [1]."/>
 <result pre="December 2019, a new coronavirus (CoV) correlated with human respiratory" exact="disease" post="was firstly reported causing pneumonia and death [1]. Soon"/>
 <result pre="(CoV) correlated with human respiratory disease was firstly reported causing" exact="pneumonia" post="and death [1]. Soon afterward, the disease cases continued"/>
 <result pre="firstly reported causing pneumonia and death [1]. Soon afterward, the" exact="disease" post="cases continued to expand and soared dramatically worldwide. The"/>
 <result pre="and soared dramatically worldwide. The causative virus, named as severe" exact="acute" post="respiratory syndrome CoV-2 (SARS-CoV-2), was identified as the pathogen"/>
 <result pre="soared dramatically worldwide. The causative virus, named as severe acute" exact="respiratory" post="syndrome CoV-2 (SARS-CoV-2), was identified as the pathogen leading"/>
 <result pre="dramatically worldwide. The causative virus, named as severe acute respiratory" exact="syndrome" post="CoV-2 (SARS-CoV-2), was identified as the pathogen leading to"/>
 <result pre="(SARS-CoV-2), was identified as the pathogen leading to the CoV" exact="disease" post="COVID-19. Infections with SARS-CoV-2 are now swift and violent,"/>
 <result pre="identified as the pathogen leading to the CoV disease COVID-19." exact="Infections" post="with SARS-CoV-2 are now swift and violent, and as"/>
 <result pre="and relevant viruses that circulate in bats, as evidenced by" exact="viral" post="genome analysis as well as the research probing into"/>
 <result pre="the past 17 years, three neoteric Î²-CoVs, SARS-CoV, Middle East" exact="respiratory" post="syndrome CoV (MERS-CoV), along with SARS-CoV-2 have emerged, engendering"/>
 <result pre="past 17 years, three neoteric Î²-CoVs, SARS-CoV, Middle East respiratory" exact="syndrome" post="CoV (MERS-CoV), along with SARS-CoV-2 have emerged, engendering severe"/>
 <result pre="of Pangolin-CoV indicated that pangolin species might be the potential" exact="intermediate" post="host for SARS-CoV-2 [7,8]. Unlike human CoVs, zoonotic viruses"/>
 <result pre="capacity of infecting both animals and humans, leading to severe" exact="respiratory" post="diseases (i.e., acute respiratory distress syndrome (ARDS) and pneumonia)"/>
 <result pre="both animals and humans, leading to severe respiratory diseases (i.e.," exact="acute" post="respiratory distress syndrome (ARDS) and pneumonia) [9,10]. Clinical data"/>
 <result pre="animals and humans, leading to severe respiratory diseases (i.e., acute" exact="respiratory" post="distress syndrome (ARDS) and pneumonia) [9,10]. Clinical data revealed"/>
 <result pre="humans, leading to severe respiratory diseases (i.e., acute respiratory distress" exact="syndrome" post="(ARDS) and pneumonia) [9,10]. Clinical data revealed that the"/>
 <result pre="elders with comorbidities, while asthma, allergic illnesses, as well as" exact="chronic" post="obstructive pulmonary disease are also risk factors [11,12]. Despite"/>
 <result pre="comorbidities, while asthma, allergic illnesses, as well as chronic obstructive" exact="pulmonary" post="disease are also risk factors [11,12]. Despite the continuous"/>
 <result pre="while asthma, allergic illnesses, as well as chronic obstructive pulmonary" exact="disease" post="are also risk factors [11,12]. Despite the continuous improvement"/>
 <result pre="Despite the continuous improvement of the prevention strategy and the" exact="disease" post="surveillance system, the lack of efficacious drug treatment and"/>
 <result pre="agents and offer some insights toward the prevention of such" exact="disease" post="based on the understanding of its epidemic dynamics in"/>
 <result pre="in real-time. 2 The epidemiology of COVID-19 Spread mainly through" exact="respiratory" post="droplets or close contact, SARS-CoV-2 induced diseases has been"/>
 <result pre="human-to-human transmission [15]. The mortality rate of SARS-CoV-2 (âˆ¼3.8%) is" exact="lower" post="compared to that of MERS-CoV (37.1%) or SARS-CoV (10%),"/>
 <result pre="of MERS-CoV (37.1%) or SARS-CoV (10%), but the number of" exact="infections" post="is more than ten times higher [16]. With respect"/>
 <result pre="source of infection, and those with severe conditions are more" exact="infectious" post="than those with mild conditions. Intriguingly, asymptomatically infected persons"/>
 <result pre="patients in incubation has also been demonstrated to shed the" exact="infectious" post="virus, serving as a potential infection source to drive"/>
 <result pre="demonstrated to shed the infectious virus, serving as a potential" exact="infection" post="source to drive the transmission of the COVID-19 [17]."/>
 <result pre="rehabilitees continuously showed a positive RT-PCR result, implicating that asymptomatic" exact="infection" post="during incubation or recovery from COVID-19 may pose a"/>
 <result pre="or recovery from COVID-19 may pose a daunting challenge to" exact="disease" post="control and prevention [18]. The incubation period refers to"/>
 <result pre="growth. Disparate models based upon the clinical progression of the" exact="disease" post="had been proposed to assess the basic reproductive ratio"/>
 <result pre="as 6.5 due to the estimation of four generations of" exact="viral" post="transmission and serried social contacts [23]. In this regard,"/>
 <result pre="confirmed cases, including 353,334 deaths (Fig. 1 ). The grand" exact="total" post="case fatality rate of global cases outside China is"/>
 <result pre="(Fig. 2 ). The matrix protein (M) along with the" exact="viral" post="envelop (E) are also located in the viral envelope"/>
 <result pre="with the viral envelop (E) are also located in the" exact="viral" post="envelope [28]. Genome analysis showed that the SARS-CoV-2 possesses"/>
 <result pre="in complex with human ACE2. (A) Schematic of SARS-CoV-2 S" exact="primary" post="structure colored by domain. SS, signal sequence; S2â€², S2â€²"/>
 <result pre="peptidase 4 for host cell entry [35]. ACE2 is a" exact="type I" post="membrane protein expressed in the lungs, hearts, kidneys, and"/>
 <result pre="in the lungs, hearts, kidneys, and intestines, mainly associated with" exact="cardiovascular" post="diseases [35]. A recent study analyzed the cryogenic electron"/>
 <result pre="is depicted in Fig. 3 . Fig. 3 The possible" exact="viral" post="entry and replication mechanism of SARS-CoV-2. When the S"/>
 <result pre="bound, the conformational change of the S protein helps the" exact="viral" post="envelope to fuse with the cell membrane through the"/>
 <result pre="RNA into the host cell. Genomic RNA is translated into" exact="viral" post="replicase polyproteins pp1a and 1ab, which are then cleaved"/>
 <result pre="and 1ab, which are then cleaved into small products by" exact="viral" post="proteases. The polymerase generates a series of subgenomic mRNAs"/>
 <result pre="mRNAs through discontinuous transcription, which is ultimately translated into related" exact="viral" post="proteins. Viral proteins and genomic RNA are subsequently assembled"/>
 <result pre="discontinuous transcription, which is ultimately translated into related viral proteins." exact="Viral" post="proteins and genomic RNA are subsequently assembled into virions"/>
 <result pre="transported through vesicles and released from the cells. ERGIC, ER-Golgi" exact="intermediate" post="compartment. Created with BioRender.com. As for the phylogenetic network"/>
 <result pre="spread outside East Asia without first mutating into a derived" exact="type B." post="Hence, SARS-CoV-2 genomes were found to be closely correlated,"/>
 <result pre="human hosts, sometimes with parallel evolutionary events, where the same" exact="viral" post="mutation occurs in two disparate human hosts [37]. Owing"/>
 <result pre="for such assays can be generated relatively quickly once the" exact="viral" post="sequence is identified (Fig. 4 ) [41]. Soon after"/>
 <result pre="criteria currently formulated by the China National Health Commission, nasopharyngeal" exact="cancer" post="and oropharyngeal swab tests have ripened into the standard"/>
 <result pre="and spike genes of SARS-CoV-2 had been inaugurated, with extremely" exact="lower" post="detection limit in vitro[42]. The SARS-CoV E gene detection"/>
 <result pre="cough or dyspnea due to exposure, the diagnosis of COVID-19" exact="infection" post="should be conducted with typical chest computerized tomography (CT)"/>
 <result pre="the diagnosis of COVID-19 infection should be conducted with typical" exact="chest" post="computerized tomography (CT) characteristics regardless of negative RT-PCR outcomes"/>
 <result pre="the COVID-19 cases shared similar characteristics on CT images, presenting" exact="bilateral" post="distribution of patchy shadows and ground-glass opacity, sometimes presenting"/>
 <result pre="shadows and ground-glass opacity, sometimes presenting a circular shape and" exact="peripheral" post="lung distribution [45]. Some of the data published from"/>
 <result pre="the data published from China showed that in 21 primal" exact="chest" post="CT scans, a large proportion of patients (86%) developed"/>
 <result pre="involvement) [46]. It is also worth noting that lung cavitation," exact="pleural" post="effusions, discrete pulmonary nodules, along with lymphadenopathy were absent"/>
 <result pre="is also worth noting that lung cavitation, pleural effusions, discrete" exact="pulmonary" post="nodules, along with lymphadenopathy were absent [46]. In addition"/>
 <result pre="Pathogenesis of SARS-CoV-2 With regard to the transmission of SARS-CoV-2," exact="primary" post="viral replication is assumed to occur in the mucosal"/>
 <result pre="of SARS-CoV-2 With regard to the transmission of SARS-CoV-2, primary" exact="viral" post="replication is assumed to occur in the mucosal epithelium"/>
 <result pre="is assumed to occur in the mucosal epithelium of the" exact="upper" post="respiratory tract and further multiplicated in the lower respiratory"/>
 <result pre="assumed to occur in the mucosal epithelium of the upper" exact="respiratory" post="tract and further multiplicated in the lower respiratory tract"/>
 <result pre="of the upper respiratory tract and further multiplicated in the" exact="lower" post="respiratory tract and gastrointestinal mucosa, inducing a mild viremia"/>
 <result pre="the upper respiratory tract and further multiplicated in the lower" exact="respiratory" post="tract and gastrointestinal mucosa, inducing a mild viremia [48]."/>
 <result pre="inducing a mild viremia [48]. At this point, very few" exact="infections" post="are under control and remain asymptomatic. Some patients may"/>
 <result pre="remain asymptomatic. Some patients may also suffer non-respiratory symptoms (i.e.," exact="acute" post="liver and heart injury, renal failure, diarrhea), suggesting multiple"/>
 <result pre="Some patients may also suffer non-respiratory symptoms (i.e., acute liver" exact="and heart" post="injury, renal failure, diarrhea), suggesting multiple organ involvement [49,50]."/>
 <result pre="patients may also suffer non-respiratory symptoms (i.e., acute liver and" exact="heart" post="injury, renal failure, diarrhea), suggesting multiple organ involvement [49,50]."/>
 <result pre="also suffer non-respiratory symptoms (i.e., acute liver and heart injury," exact="renal failure," post="diarrhea), suggesting multiple organ involvement [49,50]. Since ACE2 is"/>
 <result pre="binding to the receptor, the spike protein can catalyze the" exact="viral" post="fusion process, allowing the viral genome to enter the"/>
 <result pre="spike protein can catalyze the viral fusion process, allowing the" exact="viral" post="genome to enter the cytoplasm. A prerequisite for this"/>
 <result pre="report on the pathological results of severe COVID-19 revealed that" exact="diffuse" post="alveolar injury on both sides of the lung was"/>
 <result pre="membrane formation, suggesting ARDS. Moreover, the left lung tissue showed" exact="pulmonary" post="edema and hyaline membrane formation, implying early ARDS. Interstitial"/>
 <result pre="showed pulmonary edema and hyaline membrane formation, implying early ARDS." exact="Interstitial" post="mononuclear inflammatory infiltrates, dominated by lymphocytes, were found in"/>
 <result pre="lymphocytes, were found in both lungs. Another study reported that" exact="acute" post="kidney injury and proteinuria might also occur during the"/>
 <result pre="were found in both lungs. Another study reported that acute" exact="kidney injury" post="and proteinuria might also occur during the progression of"/>
 <result pre="in both lungs. Another study reported that acute kidney injury" exact="and proteinuria" post="might also occur during the progression of COVID-19 disease."/>
 <result pre="a few interstitial mononuclear inflammatory infiltrates were found in the" exact="heart" post="tissue, meaning that this virus may not directly induce"/>
 <result pre="heart tissue, meaning that this virus may not directly induce" exact="heart" post="impairment [53]. Aside from the acute respiratory distress syndrome,"/>
 <result pre="may not directly induce heart impairment [53]. Aside from the" exact="acute" post="respiratory distress syndrome, exuberant inflammatory responses during the infection"/>
 <result pre="not directly induce heart impairment [53]. Aside from the acute" exact="respiratory" post="distress syndrome, exuberant inflammatory responses during the infection process"/>
 <result pre="the acute respiratory distress syndrome, exuberant inflammatory responses during the" exact="infection" post="process were also observed in clinical, giving rise to"/>
 <result pre="process were also observed in clinical, giving rise to unrestrained" exact="pulmonary" post="inflammation. Of note, the virus-induced ACE2 downregulation, rapid virus"/>
 <result pre="inflammation aroused by SARS-CoV-2 [55]. The initial stage of rapid" exact="viral" post="replication would induce a large number of epithelial and"/>
 <result pre="of rapid viral replication would induce a large number of" exact="epithelial" post="and endothelial cell death, thereby facilitating the generation of"/>
 <result pre="recent research compared the transcriptional responses of SARS-CoV-2 with other" exact="respiratory" post="viruses to identify the transcriptional features that might form"/>
 <result pre="that the overall transcriptional induction of SARS-CoV-2 is abnormal. Despite" exact="viral" post="replication, the host's response to SARS-CoV-2 failed to initiate"/>
 <result pre="host's response to SARS-CoV-2 failed to initiate powerful responses of" exact="type I" post="and III interferons (IFN-I and -III), and at the"/>
 <result pre="Moreover, because the weakened immune response will further enable sustained" exact="viral" post="replication, this critical finding may explain why severe cases"/>
 <result pre="Fig. 5 The potential mechanism of SARS-CoV-2 inducing cytokine storm." exact="Increased" post="cytokine levels (IL-6, IL-10, and TNF-Î±) are associated with"/>
 <result pre="addition to the cytokine storm, several experimentations had unraveled that" exact="lymphopenia" post="is a customary characteristic of COVID-19, which may also"/>
 <result pre="protein-binding site to the cell-surface receptor (known as Glucose Regulated" exact="Protein" post="78 (GRP78)). Their outcomes unveiled that the binding between"/>
 <result pre="residues can be leveraged to design therapeutics specific against this" exact="disease" post="[60]. Of note, although inhibitors of the proteases that"/>
 <result pre="and pp1ab encoded by the ORF1a/b are subjected to two" exact="viral" post="proteases, papain-like protease (PLpro) and 3C cleavage-like protease (3CLpro)"/>
 <result pre="producing non-structural proteins (i.e., RdRp, helicases) which are correlated to" exact="viral" post="transcription and replication (Fig. 3) [4]. Therefore, enzyme inhibitors"/>
 <result pre="polyproteins of ORF 1a/b, is a crucial enzyme that mediates" exact="viral" post="replication and transcription [62]. Specifically, a Gln-residue almost always"/>
 <result pre="airway cells of the lungs, their blockage may suppress the" exact="viral" post="replication, and the acylation of cellular proteins will rarely"/>
 <result pre="innate immune response are modified with the same enzymes as" exact="viral" post="proteins, the acylation inhibitor may be limited. In addition,"/>
 <result pre="al. recently identified the host cell pathways modulated by SARS-CoV-2" exact="infection" post="and revealed that suppression of these pathways may prevent"/>
 <result pre="infection and revealed that suppression of these pathways may prevent" exact="viral" post="replication in human cells [65]. Of note, SARS-CoV-2 infection"/>
 <result pre="prevent viral replication in human cells [65]. Of note, SARS-CoV-2" exact="infection" post="profile was determined by translatome3 and proteome proteomics at"/>
 <result pre="SARS-CoV-2 can disintegrate in host cells, releasing the nucleocapsid and" exact="viral" post="RNA into the cytoplasm, and then translate ORF1a/b into"/>
 <result pre="broad-spectrum antiviral agents that have been harnessed to cure other" exact="viral" post="infections via utilizing standard tests for measuring the effects"/>
 <result pre="antiviral agents that have been harnessed to cure other viral" exact="infections" post="via utilizing standard tests for measuring the effects of"/>
 <result pre="about the production of siRNA molecules or inhibitors against specific" exact="viral" post="enzymes correlated with viral replication. Additionally, mAb targeting host"/>
 <result pre="siRNA molecules or inhibitors against specific viral enzymes correlated with" exact="viral" post="replication. Additionally, mAb targeting host receptors, inhibitors of host"/>
 <result pre="[78] A guanine analog for the treatment of influenza virus" exact="infections" post="Toyama Under clinical trial for COVID-19 (ChiCTR2000029548) Remdesivir [79]"/>
 <result pre="trial for Ebola(NCT03719586);Under phase III clinical trials for COVID-19 (NCT04252664)" exact="Type I" post="interferons IFN-Î²1 [80] Used as a treatment for multiple"/>
 <result pre="Type I interferons IFN-Î²1 [80] Used as a treatment for" exact="multiple sclerosis" post="Multiple companies Treatment of COVID-19 in the early stage"/>
 <result pre="interferons IFN-Î²1 [80] Used as a treatment for multiple sclerosis" exact="Multiple" post="companies Treatment of COVID-19 in the early stage Protease"/>
 <result pre="Chloroquine and hydroxychloroquine [81] Oral prescription drugs for treatment of" exact="malaria" post="and certain inflammatory conditions Multiple companies Under investigation in"/>
 <result pre="prescription drugs for treatment of malaria and certain inflammatory conditions" exact="Multiple" post="companies Under investigation in clinical trials for pre-exposure or"/>
 <result pre="in clinical trials for pre-exposure or post-exposure prophylaxis of SARS-CoV-2" exact="infection" post="Antibodies CR3022 [82] A SARS Cov-specific human monoclonal antibody"/>
 <result pre="infection Antibodies CR3022 [82] A SARS Cov-specific human monoclonal antibody" exact="Multiple" post="companies Experimental phase 5.3.1 Antiviral agents (I)Nucleoside Analogs Nucleoside"/>
 <result pre="analogs can interfere with cellular nucleotide synthesis pathways and terminate" exact="viral" post="genome replication through accumulating mutations and cutting off the"/>
 <result pre="[83]. Since nucleosides and nucleotides are the basic components of" exact="viral" post="nucleic acids, nucleoside analogs serve as viral RNA synthesis"/>
 <result pre="basic components of viral nucleic acids, nucleoside analogs serve as" exact="viral" post="RNA synthesis inhibitors in a wide spectrum of RNA"/>
 <result pre="the targeting ability toward RdRp, nucleoside analogs are responsible for" exact="viral" post="RNA replication [84]. Ribavirin is a guanine analog among"/>
 <result pre="a guanine analog among approved nucleoside analogs used to treat" exact="hepatitis" post="c virus and respiratory syncytial virus infections and has"/>
 <result pre="approved nucleoside analogs used to treat hepatitis c virus and" exact="respiratory" post="syncytial virus infections and has been harnessed to cure"/>
 <result pre="used to treat hepatitis c virus and respiratory syncytial virus" exact="infections" post="and has been harnessed to cure patients with SARS"/>
 <result pre="agent remain uncertain, and it may arouse adverse reactions like" exact="anemia" post="in high doses [77]. In COVID-19 therapy, ribavirin was"/>
 <result pre="interferon for stimulating the innate antiviral reaction at a relatively" exact="lower" post="dose to curtail side effects. In addition, another promising"/>
 <result pre="been approved in Japan for the therapy of influenza virus" exact="infections" post="and has also been demonstrated to suppress the replication"/>
 <result pre="has also been demonstrated to suppress the replication of Ebola," exact="yellow fever," post="enterovirus and norovirus [78]. Recently, Wang and coworkers suggested"/>
 <result pre="[90]. In the United States, the first case of SARS-CoV-2" exact="infection" post="was reported, and remdesivir was administered. The patient's clinical"/>
 <result pre="Moreover, the outcomes from the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) further demonstrated that this drug can stop"/>
 <result pre="the outcomes from the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) further demonstrated that this drug can stop some"/>
 <result pre="metabolized from remdesivir prodrug (GS-441524) may intercept RdRp early in" exact="viral" post="replication, thereby interfering with the downstream steps of the"/>
 <result pre="downstream steps of the SARS-CoV-2 replication cycle. Created with BioRender.com." exact="Type I" post="interferons designate a cluster of antiviral cytokines consisting of"/>
 <result pre="Îº subtypes, inducing large numbers of proteins that can undermine" exact="viral" post="replication in host cells [94]. Former researches have revealed"/>
 <result pre="comparison with IFN-Î± [95]. As for the clinical trial of" exact="type I" post="interferons, in China, therapy guidelines for COVID-19 recommend the"/>
 <result pre="candidates for antiviral agents, and can block the replication of" exact="viral" post="genes via binding to enzymes that are responsible for"/>
 <result pre="remdesivir was more effective than the combination therapy in reducing" exact="viral" post="load and improving the degree of pathological changes in"/>
 <result pre="for clinical improvement was 16 d, and the reduction in" exact="viral" post="RNA load among patients with severe SARS-CoV-2 did not"/>
 <result pre="differ in both cases [98].â€…Despite the disheartening outcomes, a marginally" exact="lower" post="number of deaths were observed among the patients with"/>
 <result pre="patients with lopinavir-ritonavir treatment in the late stage of this" exact="disease" post="in contrast to the standard-care group. Further, Baden and"/>
 <result pre="not particularly potent against SARS-CoV-2. The concentration neccessary to suppress" exact="viral" post="replication is relatively high as compared with the serum"/>
 <result pre="hydroxychloroquine Chloroquine, as a drug extensively utilized in anti-malaria and" exact="autoimmune diseases," post="has been found to be a potential broad-spectrum antiviral"/>
 <result pre="be a potential broad-spectrum antiviral agent [100]. It can prevent" exact="viral" post="infections via elevating the endosomal pH needed for virus-cell"/>
 <result pre="a potential broad-spectrum antiviral agent [100]. It can prevent viral" exact="infections" post="via elevating the endosomal pH needed for virus-cell fusion"/>
 <result pre="revealed that chloroquine was effective in the therapy of COVID-19-associated" exact="pneumonia" post="[102]. Wang and coworkers also conducted in vitro study,"/>
 <result pre="that it is an ideal candidate antiviral drug against SARS-CoV-2" exact="infection" post="in Vero E6 cells with EC50 value of around"/>
 <result pre="antibodies have been recommended as tools for preventing and treating" exact="viral" post="infections. Considering the relatively high RBD in SARS-CoV-2, the"/>
 <result pre="neutralization activity in vitro against SARS-CoV-2. Moreover, CB6â€…could suppress SARS-CoV-2" exact="infection" post="in rhesus monkeys at both prophylactic and treatmentâ€…settings. The"/>
 <result pre="structure analysis of RBD-bound antibody uncovered steric hindrance that suppressed" exact="viral" post="engagement with ACE2 and thereby blocked viral entry [112]."/>
 <result pre="hindrance that suppressed viral engagement with ACE2 and thereby blocked" exact="viral" post="entry [112]. These findings implicate that anti-RBD antibodies may"/>
 <result pre="entry [112]. These findings implicate that anti-RBD antibodies may be" exact="viral" post="species-specific inhibitors. Besides, most patients with severe COVID-19 suffered"/>
 <result pre="severe COVID-19. Clinical data showed quick fever control and improved" exact="respiratory" post="function [113]. Overall, the development of COVID-19-specific antibodies takes"/>
 <result pre="in the body, corticosteroids have been utilized in several serious" exact="viral" post="respiratory infections such as SARS-CoV and MERS-CoV with limited"/>
 <result pre="the body, corticosteroids have been utilized in several serious viral" exact="respiratory" post="infections such as SARS-CoV and MERS-CoV with limited benefits."/>
 <result pre="body, corticosteroids have been utilized in several serious viral respiratory" exact="infections" post="such as SARS-CoV and MERS-CoV with limited benefits. However,"/>
 <result pre="serious viral respiratory infections such as SARS-CoV and MERS-CoV with" exact="limited" post="benefits. However, in some cases, there is proof of"/>
 <result pre="benefits. However, in some cases, there is proof of delayed" exact="viral" post="clearance and increased rates of secondary infection and mortality"/>
 <result pre="is proof of delayed viral clearance and increased rates of" exact="secondary" post="infection and mortality [114]. In a study of 41"/>
 <result pre="proof of delayed viral clearance and increased rates of secondary" exact="infection" post="and mortality [114]. In a study of 41 COVID-19"/>
 <result pre="SARS therapy yielded adverse effects such as psychosis, diabetes, and" exact="avascular necrosis" post="[116]. In general, the treatment with corticosteroids may be"/>
 <result pre="last resort to improve the survival in patients with miscellaneous" exact="viral" post="infections (i.e., SARS, H5N1, H1N1, and Ebola virus infection)"/>
 <result pre="resort to improve the survival in patients with miscellaneous viral" exact="infections" post="(i.e., SARS, H5N1, H1N1, and Ebola virus infection) [117]."/>
 <result pre="immunoglobulin Abs in the plasma of patients recovering from the" exact="viral infection" post="may inhibit viremia. To date, in the previous SARS"/>
 <result pre="Abs in the plasma of patients recovering from the viral" exact="infection" post="may inhibit viremia. To date, in the previous SARS"/>
 <result pre="body temperature within three days, a decrease in Sequential Organ" exact="Failure" post="Assessment score, resolution of ARDS, and decline in viral"/>
 <result pre="Organ Failure Assessment score, resolution of ARDS, and decline in" exact="viral" post="loads [119]. During the emerging of COVID-19 infection in"/>
 <result pre="decline in viral loads [119]. During the emerging of COVID-19" exact="infection" post="in China, the National Health Commission of China also"/>
 <result pre="regarded as an alternative method for the treatment of COVID-19" exact="disease" post="in high-risk populations. During the COVID-19 outbreak in China,"/>
 <result pre="[120]. Previous studies also indicated that the patients with SARS-CoV" exact="infection" post="have benefited from TCM treatment [121], involving amelioration of"/>
 <result pre="to identify the potential therapeutic efficacy of herbal medications. 5.3.7" exact="Mesenchymal" post="stem cell therapy Stem cell therapy is also making"/>
 <result pre="Stem cell therapy is also making its way into COVID-19" exact="disease" post="treatment. Recently, some researches have demonstrated that the intravenous"/>
 <result pre="pneumonia, especially for critically ill patients [124]. As mentioned, COVID-19" exact="infection" post="may induce uncontrolled inflammatory innate reactions along with undermined"/>
 <result pre="critically ill patients [124]. As mentioned, COVID-19 infection may induce" exact="uncontrolled" post="inflammatory innate reactions along with undermined adaptive immune reactions,"/>
 <result pre="illness, 1 died, 1 developed ARDS, and 1 was in" exact="stable" post="condition [126]. This study uncovered that MSCs could reclaim"/>
 <result pre="that MSCs could reclaim the lung microenvironment, protect the alveolar" exact="epithelial" post="cells, block pulmonary fibrosis, and treat pulmonary dysfunction [124]."/>
 <result pre="reclaim the lung microenvironment, protect the alveolar epithelial cells, block" exact="pulmonary" post="fibrosis, and treat pulmonary dysfunction [124]. Notably, the FDA"/>
 <result pre="protect the alveolar epithelial cells, block pulmonary fibrosis, and treat" exact="pulmonary" post="dysfunction [124]. Notably, the FDA has also opened the"/>
 <result pre="been the most convenient way to receive H2O2 to fight" exact="viral" post="infections. The microscopic mist can easily penetrate the nostrils,"/>
 <result pre="the nostrils, sinuses and lungs, which are commonly affected by" exact="respiratory" post="diseases like COVID-19. Besides, molecular hydrogen has been verified"/>
 <result pre="[131]. Lung transplantation can be performed in advanced patients with" exact="respiratory" post="failure owing to COVID-19-related pulmonary fibrosis. As it is"/>
 <result pre="performed in advanced patients with respiratory failure owing to COVID-19-related" exact="pulmonary" post="fibrosis. As it is reported in a clinical study,"/>
 <result pre="immunogenic at 28 days post-vaccination [134]. Moreover, the Coalition for" exact="Epidemic" post="Preparedness Innovations (CEPI) is also combining efforts to espouse"/>
 <result pre="S protein in virtue of its essential role in the" exact="viral" post="infectivity. Other subsequent developments can constrain focus on other"/>
 <result pre="viral infectivity. Other subsequent developments can constrain focus on other" exact="viral" post="proteins (i.e., the N protein, and E protein). Further,"/>
 <result pre="immune system seems to initiate a shoddy response to natural" exact="infections" post="[137]. Additionally, allergic inflammation aroused by Th2 immunopathology should"/>
 <result pre="SARS-CoV, SARS-specific IgG Ab may ultimately fade away, and the" exact="peripheral" post="memory B cell response cannot be detected in recovered"/>
 <result pre="lentiviral vector expressing synthetic minigene based upon domains of selected" exact="viral" post="proteins; Shenzhen Geno-Immune Medical Institute Phase I (NCT04276896) /"/>
 <result pre="protein of SARS-CoV-2 University of Oxford Phase I/II(NCT04324606) Ad5-nCoV Adenovirus" exact="type 5" post="vector that expresses S protein CanSino Biologicals Phase I"/>
 <result pre="lentiviral vector expressing synthetic minigene based upon domains of selected" exact="viral" post="proteins Shenzhen Geno-Immune Medical Institute Phase I (NCT04299724) Experimental-phase"/>
 <result pre="chain Generex Biotechnology Human trials planned in June / Modified" exact="vaccinia" post="Ankara VLP vaccine based upon Wuhan strain of SARS-CoV-2"/>
 <result pre="in over 3.1 and over 3.7 log10 reductions in median" exact="viral" post="loads in bronchoalveolar lavage and nasal mucosa, respectively, as"/>
 <result pre="with the cooperation of the National Institute of Allergy and" exact="Infectious" post="Diseases [155]. mRNA-1273, which encodes a prefusion-stabilized form of"/>
 <result pre="the cooperation of the National Institute of Allergy and Infectious" exact="Diseases" post="[155]. mRNA-1273, which encodes a prefusion-stabilized form of the"/>
 <result pre="effects via eliciting the immune system without drawing into any" exact="infectious" post="viruses [9]. It has also been reported that the"/>
 <result pre="its Ii-Key immune system activation biotechnology to generate a COVID-19" exact="viral" post="peptide vaccine for human clinical practice [161]. 6.4 Other"/>
 <result pre="plasmacytoid dendritic cell growth after Fc-fused IL-7 treatment in the" exact="virus infection" post="models [166]. 7 Conclusions and inspirations Despite prodigious global"/>
 <result pre="dendritic cell growth after Fc-fused IL-7 treatment in the virus" exact="infection" post="models [166]. 7 Conclusions and inspirations Despite prodigious global"/>
 <result pre="overburdened and under-resourced, impelling medical workers and governors to make" exact="formerly" post="unthinkable judgments concerning the allotment of medical care. In"/>
 <result pre="direct impact of COVID-19, either by modeling studies of the" exact="viral" post="activity or via parsing out potential therapeutic options and"/>
 <result pre="its middle stage, some marked advances have been made from" exact="complete" post="genome sequencing of SARS-CoV-2 to the clinical practice of"/>
 <result pre="off the imperative actions for COVID-19 infections. Of note, in" exact="acute" post="respiratory infections, RT-PCR is commonly utilized for detecting pathogenic"/>
 <result pre="the imperative actions for COVID-19 infections. Of note, in acute" exact="respiratory" post="infections, RT-PCR is commonly utilized for detecting pathogenic viruses"/>
 <result pre="infections, RT-PCR is commonly utilized for detecting pathogenic viruses in" exact="respiratory" post="secretions. The positive rate of PCR from oropharyngeal swabs"/>
 <result pre="addition to the judicious design of novel therapeutics that target" exact="viral" post="replication or immunopathology, currently, rapid screening of therapeutic agents"/>
 <result pre="Notwithstanding, the commercial market for vaccines, especially vaccines for emerging" exact="infectious diseases," post="is confined by the high cost and time required"/>
 <result pre="to swiftly evolve our perception of all facets of SARS-CoV-2" exact="infections" post="and fill in the gaps concerning the emergence of"/>
 <result pre="learn from this epidemic that we need to improve our" exact="disease" post="monitoring and surveillance system to prevent such a serious"/>
 <result pre="disease monitoring and surveillance system to prevent such a serious" exact="disease" post="outbreak. Digital technologies such as big-data analytics, artificial intelligence,"/>
 <result pre="and surveillance system to prevent such a serious disease outbreak." exact="Digital" post="technologies such as big-data analytics, artificial intelligence, and blockchain"/>
 <result pre="changing: future epidemics will be fueled by various internal and" exact="external" post="causes. In our response, we must view pandemics as"/>
 <result pre="interests concerning the publication of this review. References References 1ChanJ.F.W.YuanS.KokK.H.ToK.K.W.ChuH.YangJ.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="publication of this review. References References 1ChanJ.F.W.YuanS.KokK.H.ToK.K.W.ChuH.YangJ.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="proximal origin of SARS-CoV-2Nat Med20201331932805 3ChanJ.F.W.LauS.K.P.WooP.C.Y.The emerging novel Middle East" exact="respiratory" post="syndrome coronavirus: the â€œknownsâ€� and â€œunknowns.â€�J Formos Med Assoc112201337238123883791"/>
 <result pre="origin of SARS-CoV-2Nat Med20201331932805 3ChanJ.F.W.LauS.K.P.WooP.C.Y.The emerging novel Middle East respiratory" exact="syndrome" post="coronavirus: the â€œknownsâ€� and â€œunknowns.â€�J Formos Med Assoc112201337238123883791 4ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronavirusesâ€&quot;drug"/>
 <result pre="therapeutic optionsNat Rev Drug Discov15201632726868298 5XiaS.LiuM.WangC.XuW.LanQ.FengS.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
 <result pre="harbors a high capacity to mediate membrane fusionCell Res202011331802008 6ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="coronavirusesNat Rev Microbiol11201383684824217413 10PeirisJ.S.M.LaiS.T.PoonL.L.M.GuanY.YamL.Y.C.LimW.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet36120031319132512711465 11YangX.YuY.XuJ.ShuH.LiuH.WuY.Clinical course and outcomes of critically ill"/>
 <result pre="Rev Microbiol11201383684824217413 10PeirisJ.S.M.LaiS.T.PoonL.L.M.GuanY.YamL.Y.C.LimW.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet36120031319132512711465 11YangX.YuY.XuJ.ShuH.LiuH.WuY.Clinical course and outcomes of critically ill patients"/>
 <result pre="11YangX.YuY.XuJ.ShuH.LiuH.WuY.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
 <result pre="140 patients infected by SARS-CoV-2 in Wuhan, ChinaAllergy002020112 13Organization W.H.Coronavirus" exact="disease" post="2019 (COVID-19): situation report, 722020. https://apps.who.int/iris/bitstream/handle/10665/331685/nCoVsitrep01Apr2020-eng.pdf. 14WuJ.T.LeungK.BushmanM.KishoreN.NiehusR.de SalazarP.M.Estimating clinical"/>
 <result pre="in Wuhan, ChinaNat Med20201531932805 15MetcalfC.J.E.LesslerJ.Opportunities and challenges in modeling emerging" exact="infectious" post="diseasesScience357201714915228706037 16AhnD.G.ShinH.J.KimM.H.LeeS.KimH.S.MyoungJ.Current status of epidemiology, diagnosis, therapeutics, and vaccines"/>
 <result pre="status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus" exact="disease" post="2019 (COVID-19)J Microbiol Biotechnol30202031332238757 17HoehlS.RabenauH.BergerA.KortenbuschM.CinatlJ.BojkovaD.Evidence of SARS-CoV-2 infection in"/>
 <result pre="novel coronavirus disease 2019 (COVID-19)J Microbiol Biotechnol30202031332238757 17HoehlS.RabenauH.BergerA.KortenbuschM.CinatlJ.BojkovaD.Evidence of SARS-CoV-2" exact="infection" post="in returning travelers from Wuhan, ChinaN Engl J Med38220201278128032069388"/>
 <result pre="Engl J Med38220201199120731995857 20BackerJ.A.KlinkenbergD.WallingaJ.Incubation period of 2019 novel coronavirus (2019-nCoV)" exact="infections" post="among travellers from Wuhan, China, 20â€&quot;28 January 2020Eurosurveillance25520202000062 21BaiY.YaoL.WeiT.TianF.JinD.Y.ChenL.Presumed"/>
 <result pre="24DelamaterP.L.StreetE.J.LeslieT.F.YangY.T.JacobsenK.H.Complexity of the basic reproduction number (R0)Emerg Infect Dis2520191 25LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019"/>
 <result pre="of the basic reproduction number (R0)Emerg Infect Dis2520191 25LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19):"/>
 <result pre="the basic reproduction number (R0)Emerg Infect Dis2520191 25LaiC.C.ShihT.P.KoW.C.TangH.J.HsuehP.R.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the"/>
 <result pre="and control of COVID-19Viruses122020372 28WuF.ZhaoS.YuB.ChenY.M.WangW.HuY.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature579202026526932015508 29LuR.ZhaoX.LiJ.NiuP.YangB.WuH.Genomic characterisation and epidemiology of 2019"/>
 <result pre="control of COVID-19Viruses122020372 28WuF.ZhaoS.YuB.ChenY.M.WangW.HuY.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature579202026526932015508 29LuR.ZhaoX.LiJ.NiuP.YangB.WuH.Genomic characterisation and epidemiology of 2019 novel"/>
 <result pre="of patients with SARSâ€�CoVâ€�2 infectionJ Med Virol92202058959432100876 31KratzelA.TodtD.V'kovskiP.SteinerS.GultomM.L.ThaoT.T.N.Inactivation of severe" exact="acute" post="respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations"/>
 <result pre="patients with SARSâ€�CoVâ€�2 infectionJ Med Virol92202058959432100876 31KratzelA.TodtD.V'kovskiP.SteinerS.GultomM.L.ThaoT.T.N.Inactivation of severe acute" exact="respiratory" post="syndrome coronavirus 2 by WHO-recommended hand rub formulations and"/>
 <result pre="with SARSâ€�CoVâ€�2 infectionJ Med Virol92202058959432100876 31KratzelA.TodtD.V'kovskiP.SteinerS.GultomM.L.ThaoT.T.N.Inactivation of severe acute respiratory" exact="syndrome" post="coronavirus 2 by WHO-recommended hand rub formulations and alcoholsEmerg"/>
 <result pre="sequence-validated loop-mediated isothermal amplification assays for detection of Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)PLoS One42015e0123126 41SheridanC.Fast, portable tests come online"/>
 <result pre="loop-mediated isothermal amplification assays for detection of Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)PLoS One42015e0123126 41SheridanC.Fast, portable tests come online to"/>
 <result pre="testingRadiology2020200343 45Kanne J.P.Chest CT findings in 2019 novel coronavirus (2019-nCoV)" exact="infections" post="from Wuhan, China: key points for the radiologist2020;295:16â€&quot;17 46ChungM.BernheimA.MeiX.ZhangN.HuangM.ZengX.CT"/>
 <result pre="coronavirus SARS-CoV-2 using CRISPR diagnostics: SARS-CoV-22020. https://mammoth.bio/wp-content/uploads/2020/04/200423-A-protocol-for-rapid-detection-of-SARS-CoV-2-using-CRISPR-diagnostics_3.pdf. 48XiaoF.TangM.ZhengX.LiC.HeJ.HongZ.Evidence for gastrointestinal" exact="infection" post="of SARS-CoV-2Gastroenterology15820201831183332142773 49HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of patients infected with 2019"/>
 <result pre="50WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, ChinaJAMA32311202010611069 51ZouX.ChenK.ZouJ.HanP.HaoJ.HanZ.Single-cell RNA-seq data analysis on the"/>
 <result pre="clinically proven protease inhibitorCell181202027128032142651 53XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med8202042042232085846 54SuH.YangM.WanC.YiL.X.TangF.ZhuH.Y.Renal histopathological analysis of"/>
 <result pre="proven protease inhibitorCell181202027128032142651 53XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med8202042042232085846 54SuH.YangM.WanC.YiL.X.TangF.ZhuH.Y.Renal histopathological analysis of 26"/>
 <result pre="drives development of COVID-19Cell18120201036104532416070 58ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med382202072773331978945 59YuanK.YiL.ChenJ.QuX.QingT.RaoX.Suppression of SARS-CoV"/>
 <result pre="64GadallaM.R.VeitM.Toward the identification of ZDHHC enzymes required for palmitoylation of" exact="viral" post="protein as potential drug targetsExpert Opin Drug Discov15202015917731809605 65BojkovaD.KlannK.KochB.WideraM.KrauseD.CiesekS.Proteomics"/>
 <result pre="BoheemenS.de GraafM.LauberC.BestebroerT.M.RajV.S.ZakiA.M.Genomic characterization of a newly discovered coronavirus associated with" exact="acute" post="respiratory distress syndrome in humansMBio32012e00412e00473 67ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.Y.Severe acute respiratory syndrome"/>
 <result pre="GraafM.LauberC.BestebroerT.M.RajV.S.ZakiA.M.Genomic characterization of a newly discovered coronavirus associated with acute" exact="respiratory" post="distress syndrome in humansMBio32012e00412e00473 67ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.Y.Severe acute respiratory syndrome coronavirus"/>
 <result pre="of a newly discovered coronavirus associated with acute respiratory distress" exact="syndrome" post="in humansMBio32012e00412e00473 67ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.Y.Severe acute respiratory syndrome coronavirus as an"/>
 <result pre="coronavirus associated with acute respiratory distress syndrome in humansMBio32012e00412e00473 67ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.Y.Severe" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
 <result pre="associated with acute respiratory distress syndrome in humansMBio32012e00412e00473 67ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.Y.Severe acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
 <result pre="with acute respiratory distress syndrome in humansMBio32012e00412e00473 67ChengV.C.C.LauS.K.P.WooP.C.Y.YuenK.Y.Severe acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infectionClin"/>
 <result pre="of arbidol and its derivatives against the pathogen of severe" exact="acute" post="respiratory syndrome in the cell culturesVopr Virusol532008913 69CinatlJ.MorgensternB.BauerG.ChandraP.RabenauH.DoerrH.W.Treatment of"/>
 <result pre="arbidol and its derivatives against the pathogen of severe acute" exact="respiratory" post="syndrome in the cell culturesVopr Virusol532008913 69CinatlJ.MorgensternB.BauerG.ChandraP.RabenauH.DoerrH.W.Treatment of SARS"/>
 <result pre="and its derivatives against the pathogen of severe acute respiratory" exact="syndrome" post="in the cell culturesVopr Virusol532008913 69CinatlJ.MorgensternB.BauerG.ChandraP.RabenauH.DoerrH.W.Treatment of SARS with"/>
 <result pre="70DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.Repurposing of clinically developed drugs for treatment of Middle East" exact="respiratory" post="syndrome coronavirus infectionAntimicrob Agents Chemother5820144885489324841273 71KindrachukJ.OrkB.HartB.J.MazurS.HolbrookM.R.FriemanM.B.Antiviral potential of ERK/MAPK"/>
 <result pre="of clinically developed drugs for treatment of Middle East respiratory" exact="syndrome" post="coronavirus infectionAntimicrob Agents Chemother5820144885489324841273 71KindrachukJ.OrkB.HartB.J.MazurS.HolbrookM.R.FriemanM.B.Antiviral potential of ERK/MAPK and"/>
 <result pre="potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East" exact="respiratory" post="syndrome coronavirus infection as identified by temporal kinome analysisAntimicrob"/>
 <result pre="of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory" exact="syndrome" post="coronavirus infection as identified by temporal kinome analysisAntimicrob Agents"/>
 <result pre="and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus" exact="infection" post="as identified by temporal kinome analysisAntimicrob Agents Chemother5920151088109925487801 72ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.Identification"/>
 <result pre="Chemother5920151088109925487801 72ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.Identification of a broad-spectrum antiviral small molecule against severe" exact="acute" post="respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses"/>
 <result pre="72ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.Identification of a broad-spectrum antiviral small molecule against severe acute" exact="respiratory" post="syndrome coronavirus and Ebola, Hendra, and Nipah viruses by"/>
 <result pre="of a broad-spectrum antiviral small molecule against severe acute respiratory" exact="syndrome" post="coronavirus and Ebola, Hendra, and Nipah viruses by using"/>
 <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488424841269 74QueT.L.WongV.C.W.YuenK.Y.Treatment"/>
 <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488424841269 74QueT.L.WongV.C.W.YuenK.Y.Treatment of"/>
 <result pre="coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488424841269 74QueT.L.WongV.C.W.YuenK.Y.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
 <result pre="replication in cell cultureAntimicrob Agents Chemother5820144875488424841269 74QueT.L.WongV.C.W.YuenK.Y.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
 <result pre="in cell cultureAntimicrob Agents Chemother5820144875488424841269 74QueT.L.WongV.C.W.YuenK.Y.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
 <result pre="and interferon therapy in patients infected with the Middle East" exact="respiratory" post="syndrome coronavirus: an observational studyInt J Infect Dis202014424624406736 78De"/>
 <result pre="interferon therapy in patients infected with the Middle East respiratory" exact="syndrome" post="coronavirus: an observational studyInt J Infect Dis202014424624406736 78De ClercqE.New"/>
 <result pre="talk between nucleotide synthesis pathways with cellular immunity in constraining" exact="hepatitis E" post="virus replicationAntimicrob Agents Chemother6020162834284826926637 84DebingY.EmersonS.U.WangY.PanQ.BalzariniJ.DallmeierK.Ribavirin inhibits in vitro hepatitis"/>
 <result pre="hepatitis E virus replicationAntimicrob Agents Chemother6020162834284826926637 84DebingY.EmersonS.U.WangY.PanQ.BalzariniJ.DallmeierK.Ribavirin inhibits in vitro" exact="hepatitis E" post="virus replication through depletion of cellular GTP pools and"/>
 <result pre="Agents Chemother58201426727324145541 85SoL.K.Y.LauA.C.W.YamL.Y.C.CheungT.M.T.PoonE.YungR.W.H.Development of a standard treatment protocol for severe" exact="acute" post="respiratory syndromeLancet36120031615161712747883 86WenzelR.P.EdmondM.B.Managing SARS amidst uncertaintyN Engl J Med34820031947194812748313"/>
 <result pre="Chemother58201426727324145541 85SoL.K.Y.LauA.C.W.YamL.Y.C.CheungT.M.T.PoonE.YungR.W.H.Development of a standard treatment protocol for severe acute" exact="respiratory" post="syndromeLancet36120031615161712747883 86WenzelR.P.EdmondM.B.Managing SARS amidst uncertaintyN Engl J Med34820031947194812748313 87MorgensternB.MichaelisM.BaerP.C.DoerrH.W.Ribavirin"/>
 <result pre="Rev14200177880911585785 95ScagnolariC.VicenziE.BellomiF.StillitanoM.G.PinnaD.PoliG.Increased sensitivity of SARS-coronavirus to a combination of human" exact="type I" post="and type II interferonsAntivir Ther920041003101115651759 96DongL.HuS.GaoJ.Discovering drugs to treat"/>
 <result pre="of SARS-coronavirus to a combination of human type I and" exact="type II" post="interferonsAntivir Ther920041003101115651759 96DongL.HuS.GaoJ.Discovering drugs to treat coronavirus disease 2019"/>
 <result pre="and type II interferonsAntivir Ther920041003101115651759 96DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov Ther142020586032147628 97WuC.Y.JanJ.T.MaS.H.KuoC.J.JuanH.F.ChengY.S.E.Small molecules targeting severe acute"/>
 <result pre="coronavirus disease 2019 (COVID-19)Drug Discov Ther142020586032147628 97WuC.Y.JanJ.T.MaS.H.KuoC.J.JuanH.F.ChengY.S.E.Small molecules targeting severe" exact="acute" post="respiratory syndrome human coronavirusProc Natl Acad Sci1012004100121001715226499 98CaoB.WangY.WenD.A trial"/>
 <result pre="disease 2019 (COVID-19)Drug Discov Ther142020586032147628 97WuC.Y.JanJ.T.MaS.H.KuoC.J.JuanH.F.ChengY.S.E.Small molecules targeting severe acute" exact="respiratory" post="syndrome human coronavirusProc Natl Acad Sci1012004100121001715226499 98CaoB.WangY.WenD.A trial of"/>
 <result pre="2019 (COVID-19)Drug Discov Ther142020586032147628 97WuC.Y.JanJ.T.MaS.H.KuoC.J.JuanH.F.ChengY.S.E.Small molecules targeting severe acute respiratory" exact="syndrome" post="human coronavirusProc Natl Acad Sci1012004100121001715226499 98CaoB.WangY.WenD.A trial of lopinavir-ritonavir"/>
 <result pre="Infect Dis62006676916439323 101VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056916115318 102GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends4120207273 103JallouliM.GalicierL.ZahrN.AumaitreO.FrancesC.Le GuernV.Determinants of hydroxychloroquine blood"/>
 <result pre="studiesBiosci Trends4120207273 103JallouliM.GalicierL.ZahrN.AumaitreO.FrancesC.Le GuernV.Determinants of hydroxychloroquine blood concentration variations in" exact="systemic" post="lupus erythematosusArthritis Rheumatol6720152176218425989906 104BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.Design and synthesis of hydroxyferroquine derivatives"/>
 <result pre="Trends4120207273 103JallouliM.GalicierL.ZahrN.AumaitreO.FrancesC.Le GuernV.Determinants of hydroxychloroquine blood concentration variations in systemic" exact="lupus" post="erythematosusArthritis Rheumatol6720152176218425989906 104BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.Design and synthesis of hydroxyferroquine derivatives with"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020ciaa237 106SchrezenmeierE.DÃ¶rnerT.Mechanisms of"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020ciaa237 106SchrezenmeierE.DÃ¶rnerT.Mechanisms of action"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020ciaa237 106SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of"/>
 <result pre="does not support corticosteroid treatment for 2019-nCoV lung injuryLancet395202047347532043983 115ZhouM.ZhangX.QuJ.Coronavirus" exact="disease" post="2019 (COVID-19): a clinical updateFront Med142202012613532240462 116LeeN.ChanK.C.A.HuiD.S.NgE.K.O.WuA.ChiuR.W.K.Effects of early"/>
 <result pre="early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in" exact="adult" post="patientsJ Clin Virol31200430430915494274 117ChenL.XiongJ.BaoL.ShiY.Convalescent plasma as a potential therapy"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis2112015809025030060"/>
 <result pre="120DuH.Z.HouX.Y.MiaoY.H.HuangB.S.LiuD.H.Traditional chinese medicine: an effective treatment for 2019 novel coronavirus" exact="pneumonia" post="(NCP)Chin J Nat Med18202020621032245590 121LiuX.ZhangM.HeL.LiY.Chinese herbs combined with Western"/>
 <result pre="Nat Med18202020621032245590 121LiuX.ZhangM.HeL.LiY.Chinese herbs combined with Western medicine for severe" exact="acute" post="respiratory syndrome (SARS)Cochrane Database Syst Rev2512012CD004882 122LiR.F.HouY.L.HuangJ.C.PanW.Q.MaQ.H.ShiY.X.Lianhuaqingwen exerts anti-viral"/>
 <result pre="Med18202020621032245590 121LiuX.ZhangM.HeL.LiY.Chinese herbs combined with Western medicine for severe acute" exact="respiratory" post="syndrome (SARS)Cochrane Database Syst Rev2512012CD004882 122LiR.F.HouY.L.HuangJ.C.PanW.Q.MaQ.H.ShiY.X.Lianhuaqingwen exerts anti-viral and"/>
 <result pre="121LiuX.ZhangM.HeL.LiY.Chinese herbs combined with Western medicine for severe acute respiratory" exact="syndrome" post="(SARS)Cochrane Database Syst Rev2512012CD004882 122LiR.F.HouY.L.HuangJ.C.PanW.Q.MaQ.H.ShiY.X.Lianhuaqingwen exerts anti-viral and anti-inflammatory"/>
 <result pre="wound healingJ Transl Sci6202016 131Hydrogen molecular biomedicine promotes new coronary" exact="pneumonia" post="diagnosis and treatment plan. https://www.sohu.com/a/375239106_99929695 132ChenJ.Y.QiaoK.LiuF.WuB.XuX.JiaoG.Q.Lung transplantation as therapeutic"/>
 <result pre="and treatment plan. https://www.sohu.com/a/375239106_99929695 132ChenJ.Y.QiaoK.LiuF.WuB.XuX.JiaoG.Q.Lung transplantation as therapeutic option in" exact="acute" post="respiratory distress syndrome for COVID-19-related pulmonary fibrosisChin Med J13320201390139632251003"/>
 <result pre="treatment plan. https://www.sohu.com/a/375239106_99929695 132ChenJ.Y.QiaoK.LiuF.WuB.XuX.JiaoG.Q.Lung transplantation as therapeutic option in acute" exact="respiratory" post="distress syndrome for COVID-19-related pulmonary fibrosisChin Med J13320201390139632251003 133AndrÃ©F.E.The"/>
 <result pre="https://www.sohu.com/a/375239106_99929695 132ChenJ.Y.QiaoK.LiuF.WuB.XuX.JiaoG.Q.Lung transplantation as therapeutic option in acute respiratory distress" exact="syndrome" post="for COVID-19-related pulmonary fibrosisChin Med J13320201390139632251003 133AndrÃ©F.E.The future of"/>
 <result pre="as therapeutic option in acute respiratory distress syndrome for COVID-19-related" exact="pulmonary" post="fibrosisChin Med J13320201390139632251003 133AndrÃ©F.E.The future of vaccines, immunisation concepts"/>
 <result pre="pursuit of a COVID-19 vaccineProc Natl Acad Sci117152020202005456 138TangF.QuanY.XinZ.T.WrammertJ.MaM.J.LvH.Lack of" exact="peripheral" post="memory B cell responses in recovered patients with severe"/>
 <result pre="peripheral memory B cell responses in recovered patients with severe" exact="acute" post="respiratory syndrome: a six-year follow-up studyJ Immunol18620117264726821576510 139Jiang S.B.Don't"/>
 <result pre="memory B cell responses in recovered patients with severe acute" exact="respiratory" post="syndrome: a six-year follow-up studyJ Immunol18620117264726821576510 139Jiang S.B.Don't rush"/>
 <result pre="https://pipelinereview.com/index.php/2020040674247/Vaccines/INOVIO-Initiates-Phase-1-Clinical-Trial-Of-Its-COVID-19-Vaccine-and-Plans-First-Dose-Today.html. 151YuJ.Y.TostanoskiL.H.PeterL.MercadoN.B.McMahanK.MahrokhianS.H.DNA vaccine protection against SARS-CoV-2 in rhesus macaquesScience2020eabc6284 152ChandrashekarA.LiuJ.MartinotA.J.McMahanK.MercadoN.B.PeterL.SARS-CoV-2" exact="infection" post="protects against rechallenge in rhesus macaquesScience2020eabc4776 153Inovio's DNA-encoded monoclonal"/>
 <result pre="COVID-19. https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19. 156mRNA platform: enabling drug discovery&amp;amp;development. https://www.modernatx.com/mrna-technology/mrna-platform-enabling-drug-discovery-development. 157OkbaN.M.A.RajV.S.HaagmansB.L.Middle East" exact="respiratory" post="syndrome coronavirus vaccines: current status and novel approachesCurr Opin"/>
 <result pre="https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19. 156mRNA platform: enabling drug discovery&amp;amp;development. https://www.modernatx.com/mrna-technology/mrna-platform-enabling-drug-discovery-development. 157OkbaN.M.A.RajV.S.HaagmansB.L.Middle East respiratory" exact="syndrome" post="coronavirus vaccines: current status and novel approachesCurr Opin Virol232017495828412285"/>
</results>
